- Home
- OGI vs LCTX Comparison
OGI vs LCTX Comparison
Compare OGI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- LCTX
- Stock Information
- Founded
- OGI 2013
- LCTX 1990
- Country
- OGI Canada
- LCTX United States
- Employees
- OGI N/A
- LCTX N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- LCTX Health Care
- Exchange
- OGI Nasdaq
- LCTX Nasdaq
- Market Cap
- OGI 176.1M
- LCTX 165.6M
- IPO Year
- OGI N/A
- LCTX N/A
- Fundamental
- Price
- OGI $1.90
- LCTX $0.91
- Analyst Decision
- OGI
- LCTX Strong Buy
- Analyst Count
- OGI 0
- LCTX 3
- Target Price
- OGI N/A
- LCTX $5.67
- AVG Volume (30 Days)
- OGI 424.2K
- LCTX 309.4K
- Earning Date
- OGI 08-13-2024
- LCTX 11-07-2024
- Dividend Yield
- OGI N/A
- LCTX N/A
- EPS Growth
- OGI N/A
- LCTX N/A
- EPS
- OGI N/A
- LCTX N/A
- Revenue
- OGI $110,297,722.00
- LCTX $6,186,000.00
- Revenue This Year
- OGI $8.76
- LCTX N/A
- Revenue Next Year
- OGI $14.04
- LCTX $119.00
- P/E Ratio
- OGI N/A
- LCTX N/A
- Revenue Growth
- OGI 2.33
- LCTX N/A
- 52 Week Low
- OGI $0.97
- LCTX $0.77
- 52 Week High
- OGI $2.91
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- OGI 57.16
- LCTX 53.57
- Support Level
- OGI $1.76
- LCTX $0.83
- Resistance Level
- OGI $1.92
- LCTX $0.94
- Average True Range (ATR)
- OGI 0.08
- LCTX 0.05
- MACD
- OGI -0.00
- LCTX 0.01
- Stochastic Oscillator
- OGI 95.00
- LCTX 86.36
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.